What Week 6 of Wegovy Actually Looks Like

The decision most people face at week 6: stay or step up?

Wegovy's titration schedule is designed with a specific rhythm. You start at 0.25 mg for four weeks, move to 0.5 mg for another four, and week 6 puts you squarely in the middle of that 0.5 mg phase. Some people feel stable and notice a clear shift in hunger. Others are still adjusting. Neither is a sign that something has gone wrong.

The question worth holding in your head at this stage isn't "why haven't I lost more weight?" but "is my body tolerating this well enough to move forward?" That's the actual clinical decision: your prescriber will look at how you've responded to 0.5 mg before recommending the step to 1 mg. As the NHS's semaglutide guidance notes, the dose escalation is there to reduce the chance of side effects, not to withhold treatment.

If you're tracking things week by week, the broader Wegovy week-by-week guide maps the full titration arc, which can help you orient week 6 within the longer picture. The short version: you are not yet at a therapeutic maintenance dose, and that context matters when you're assessing results so far.

Side effects at week 6: what's normal, what's worth flagging

A common misconception is that side effects should have completely resolved by now. The reality is more nuanced. For many people, nausea, loose stools or a general sense of fullness that tips into discomfort does ease considerably by the time they reach week 5, and often continues to settle into week 6. But if you're about to increase your dose, a milder rerun of those early symptoms in weeks 7 or 8 is not unusual. The body is adjusting again.

The side effects associated with semaglutide are predominantly gastrointestinal: nausea, constipation, diarrhoea, indigestion and burping are the most commonly reported. Fatigue and headache show up for some people too. These are described in detail in the NHS medicines page for semaglutide, and it's worth reading through them if you haven't already.

There are symptoms that do warrant prompt medical attention: severe, persistent stomach pain that spreads to the back could indicate pancreatitis, which is an infrequent but serious risk the MHRA has flagged for GLP-1 medicines. Gallbladder symptoms, signs of a serious allergic reaction, or significant dehydration from ongoing vomiting or diarrhoea should all prompt a call to your GP or prescriber rather than a wait-and-see approach. If you're treating with nume, our aftercare team is available seven days a week. You can also find practical support in our FAQs.

What the weight-loss numbers usually look like at this point

People often arrive at week 6 having lost somewhere between two and five kilograms, though the range is genuinely wide. Factors like starting weight, diet, activity, sleep, stress and individual metabolic response all shift the picture. A person who has lost 1.5 kg is not failing; a person who has lost 6 kg is not unusual either.

The STEP 1 trial, published in the New England Journal of Medicine, showed an average weight reduction of around 15% over 68 weeks at the 2.4 mg maintenance dose. That landmark figure comes from a full 68-week course, not six weeks. Week 6 is early. The trajectory matters more than the total at this stage, and appetite changes, food noise quietening, and better control around meals are meaningful signals even when the scales are moving slowly.

If you're curious about what results tend to look like over a longer window, the six-week weight loss picture goes into more detail on realistic expectations at this milestone. For context on how the journey develops from here, our guide to week 9 covers what typically happens as you move through the later dose increases and the week 7 guide covers what typically happens as the dose steps up.

Keeping the next few weeks on track

Week 6 is a reasonable moment to take stock. Protein intake matters more on this treatment than many people expect: semaglutide reduces overall appetite, and if meals shrink without any attention to composition, muscle loss can become a concern. Staying hydrated, prioritising fibre, and keeping some form of regular movement in the week all support the medicine rather than just accompanying it.

The treatment works best alongside dietary changes, not instead of them. That framing is built into the licence: Wegovy is approved for use alongside a reduced-calorie diet and increased physical activity, per the NICE guidance under NICE TA875. Your prescriber or a registered dietitian is the right person to help you build that picture for your own circumstances.

If you haven't yet started Wegovy and are weighing up whether this is the right route, checking your eligibility through a free consultation is the place to start. A named prescriber reviews every application; there's no automated decision.